Tvardi Therapeutics is trading 6.13% higher at $1.12 after investors responded to September 24 preclinical data on TTI-101, its oral STAT3 inhibitor. - The study found drug concentrations approximately eight times higher in colon tissue than plasma. - In a mouse model, TTI-101 prevented colon polyps and adenocarcinomas, providing additional support for Tvardi’s ulcerative-colitis development strategy. - Shares had fallen to $1.06 on September 24, while broader markets were only modestly higher, indicating the research update was the primary catalyst.